Abbott India Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company delivered a robust performance, reporting an annual revenue from operations of ₹6,929.05 crore and a net profit of ₹1,552.02 crore. The Board of Directors has recommended a final dividend of ₹525 and a special dividend of ₹131 per equity share to reward shareholders.
Annual Financial Performance
For the financial year ended March 31, 2026, Abbott India Limited achieved a significant increase in its top-line, with revenue from operations reaching ₹6,929.05 crore, compared to ₹6,409.15 crore in the previous fiscal year. The company’s total income for the year stood at ₹7,217.19 crore. Profit after tax for the full year grew to ₹1,552.02 crore, reflecting solid operational efficiency and sustained market demand for its pharmaceutical portfolio.
Quarterly Highlights
In the fourth quarter (January–March 2026), the company reported revenue from operations of ₹1,709.51 crore. Profit for the same period was recorded at ₹394.93 crore, showing consistent growth compared to the profit of ₹367.04 crore reported in the same quarter of the previous year.
Dividend Recommendations
Reflecting the company’s strong financial position, the Board of Directors has recommended a generous dividend payout. Shareholders can expect a final dividend of ₹525 per share, supplemented by a special dividend of ₹131 per share, both for equity shares with a face value of ₹10 each. This recommendation is subject to the approval of shareholders at the upcoming Annual General Meeting.
Operational Context
During the fiscal year, the company proactively adjusted its cost structure, including recognizing an incremental cost of ₹18.10 crore related to the implementation of new labor codes. Abbott India continues to operate as a single-segment entity focused on the pharmaceuticals sector, maintaining its focus on operational excellence and long-term value creation.
Source: BSE
